Alaunos Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $4.4M
- Website
- http://www.alaunos.com
- Introduction
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Phase 2
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 67
- Registration Number
- NCT00718484
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00608803
Study of Oral Palifosfamide Tris in Solid Tumors
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT00607711
Phase I Study of Indibulin in Patients With Solid Tumors
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 47
- Registration Number
- NCT00591136
Phase I Study in Advanced Solid Tumors
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT00591292
A Phase I Trial of ZIO-101 in Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: ZIO-101 (Darinaparsin)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT00591396
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Phase 1
- Conditions
- Advanced Solid TumorsLymphomas
- Interventions
- Drug: ZIO-101-C (Darinaparsin)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT00592163
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Phase 1
- Conditions
- Advanced Cancer
- Interventions
- Drug: ZIO-101-C (Darinaparsin)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00591422
A Phase I Trial of ZIO-101 in Hematologic Cancers
Phase 1
Completed
- Conditions
- Acute LeukemiaChronic Myeloproliferative DiseaseChronic Lymphoproliferative DiseaseMultiple MyelomaLymphomaPoor-risk Myelodysplasia (MDS)
- Interventions
- Drug: ZIO-101 (Darinaparsin)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00592046
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT00591890
© Copyright 2025. All Rights Reserved by MedPath